Innovent Announces Phase 3 RESTORE-3 Study of SYCUME® (Teprotumumab N01 Injection) Met Primary Endpoint in Inactive Thyroid Eye Disease

What happened: Innovent said its Phase 3 RESTORE-3 study of SYCUME (Teprotumumab N01 Injection, IBI311) met its primary endpoint at Week 24 in Chinese participants with inactive thyroid eye disease. Key numbers: 116 participants randomized about 2:1 to IBI311 or placebo. Why it matters: The company said the results mark a milestone for SYCUME in full-course TED management, with patients with inactive TED making up roughly two-thirds of the overall TED population. SYCUME was included in China's National Reimbursement Drug List on January 1, 2026. Market: -1.2% by next close ($91.65 on Oct 12), +13.5% YTD

Innovent said its Phase 3 RESTORE-3 study of SYCUME (Teprotumumab N01 Injection, IBI311) met its primary endpoint at Week 24 in Chinese participants with inactive thyroid eye disease.

The company said the results mark a milestone for SYCUME in full-course TED management, with patients with inactive TED making up roughly two-thirds of the overall TED population. SYCUME was included in China's National Reimbursement Drug List on January 1, 2026. Market: -1.2% by next close ($91.65 on Oct 12), +13.5% YTD